1. Search Result
Search Result
Results for "

ventral

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Fluorescent Dyes

3

Peptides

8

Natural
Products

3

Recombinant Proteins

1

Isotope-Labeled Compounds

1

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0451A
    Dopamine hydrochloride
    20+ Cited Publications

    ASL279

    Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine hydrochloride
  • HY-B0451
    Dopamine
    20+ Cited Publications

    ASL279 free base

    Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine plays several important roles in the brain and body . Dopamine acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine
  • HY-13409
    SB 242084
    5+ Cited Publications

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084
  • HY-12363
    U-69593
    1 Publications Verification

    Opioid Receptor Neurological Disease
    U-69593 is a potent and selective κ1-opioid receptor agonist . U-69593 attenuates addictive agent-induced behavioral sensitization in the rat . U-69593 reduces anxiety and enhances spontaneous alternation memory in mice . U-69593 reduces calcium-dependent dialysate levels of dopamine and glutamate in the ventral striatum .
    U-69593
  • HY-172550

    HCN Channel Neurological Disease
    MS7710 is a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel inhibitor with blood-brain barrier permeability and an excellent brain/plasma concentration ratio. MS7710 inhibits HCN channel-mediated Ih current, and reduces the firing frequency and burst activity of dopaminergic neurons in the ventral tegmental area. MS7710 ameliorates chronic social defeat stress-induced deficits in social interaction and impairments in reward-related cognitive flexibility in mice. MS7710 exerts only limited effects on ventral tegmental area dopaminergic neuron activity, social interaction, exploratory behavior, locomotor activity or sucrose preference in control mice. MS7710 is applicable to the research of major depressive disorder .
    MS7710
  • HY-B0451AR

    ASL279 (Standard)

    Reference Standards Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine hydrochloride (Standard)
  • HY-13409A
    SB 242084 dihydrochloride
    5+ Cited Publications

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084 dihydrochloride
  • HY-W067716

    (S)-Spinacine

    GABA Receptor Neurological Disease
    Spinacine ((S)-Spinacine) is a GABA uptake inhibitor. Spinacine enhances synaptic GABA effects via inhibition of gamma-aminobutyric acid uptake in cerebral cortex slices. Spinacine inhibits reflex responses of ventral roots in isolated spinal cord. Spinacine inhibits motor activity and reduces approaches to water dispensers in conflict situations. Spinacine raises pain sensitivity threshold via subarachnoidal injection .
    Spinacine
  • HY-B0451AS7

    ASL279-d5 hydrochloride

    Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite Ferroptosis Neurological Disease
    Dopamine-d5 (hydrochloride) is the deuterium labeled Dopamine (hydrochloride). Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Dopamine-d5 hydrochloride
  • HY-148502
    VU6019650
    2 Publications Verification

    mAChR Neurological Disease
    VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) .
    VU6019650
  • HY-147319

    Trace Amine-associated Receptor (TAAR) Neurological Disease
    RTI-7470-44 is a potent, selective and blood-brain barrier (BBB) penetrant human trace amine-associated receptor subtype 1 (hTAAR1) antagonist with an IC50 value of 8.4 nM and a Ki value of 0.3 nM. RTI-7470-44 has moderate metabolic stability, and a favorable preliminary off-target profile. RTI-7470-44 can increase the spontaneous firing rate of mouse ventral tegmental area (VTA) dopaminergic neurons. RTI-7470-44 can be used for researching schizophrenia, agent addiction, and Parkinson’s disease (PD) .
    RTI-7470-44
  • HY-17375
    Allylestrenol
    1 Publications Verification

    Progesterone Receptor Androgen Receptor Endocrinology
    Allylestrenol is an orally active synthetic anti-androgen sexualsteroid. Allylestrenol can prevent miscarriage in vivo. Allylestrenol significantly affects testosterone progesterone level in rat model. Allylestrenol can reduce ventral prostate weight in rat model .
    Allylestrenol
  • HY-103197

    RX821002 hydrochloride

    Adrenergic Receptor Neurological Disease
    2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride) is a highly selective alpha 2-adrenoceptor antagonist with little or no imidazoline antagonist effect. RX 821002 has markedly higher affinity for (guinea-pig) alpha 2D-adrenoceptors (pKd 9.7) than for (rabbit) alpha 2A-adrenoceptors (pKd 8.2) .
    2-Methoxyidazoxan monohydrochloride
  • HY-15691

    Opioid Receptor mTOR Neurological Disease Metabolic Disease
    PF-04455242 is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-04455242 blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-04455242 promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-04455242 attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-04455242 can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
    PF-04455242
  • HY-113316A

    Endogenous Metabolite Opioid Receptor Neurological Disease
    (±)-Salsolinol hydrochloride is the hydrochloride form of (±)-Salsolinol (HY-113316). (±)-Salsolinol hydrochloride is a Dopamine (HY-B0451)-derived endogenous metabolite. (±)-Salsolinol hydrochloride activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (±)-Salsolinol hydrochloride
  • HY-P1329A
    CTOP TFA
    1 Publications Verification

    Opioid Receptor Neurological Disease
    CTOP TFA is a potent and highly selective μ-opioid receptor antagonist. CTOP TFA antagonizes the acute analgesic effect and hypermotility. CTOP TFA enhances extracellular dopamine levels in the nucleus accumbens. CTOP TFA dose-dependently enhances locomotor activity .
    CTOP TFA
  • HY-19432

    iGluR Neurological Disease
    UBP-282 is a potent, selective and competitive AMPA and kainate receptor antagonist. UBP-282 inhibits the fast component of the dorsal root-evoked ventral root potential (fDR-VRP) with an IC50 value of 10.3 μM. UBP-282 antagonizes kainate-induced depolarisations of dorsal roots with a pA2 value of 4.96 .
    UBP-282
  • HY-P1329

    Opioid Receptor Neurological Disease
    CTOP is a potent and highly selective μ-opioid receptor antagonist. CTOP antagonizes the acute morphine-induced analgesic effect and hypermotility. CTOP enhances extracellular dopamine levels in the nucleus accumbens. CTOP dose-dependently enhances locomotor activity .
    CTOP
  • HY-118834

    Lyngbyatoxin A

    PKC Inflammation/Immunology Cancer
    Teleocidin A1 (Lyngbyatoxin A) is a PKC activator with a Ki value of 0.11 nM for binding to the PKCδ-C1B peptide. Teleocidin A1 exhibits anticancer activity against cervical cancer and leukemia. Teleocidin A1 can induce seaweed dermatitis, food poisoning and local skin toxicity. Teleocidin A1 can be used in studies related to cervical cancer, seaweed dermatitis and food poisoning .
    Teleocidin A1
  • HY-W067716R

    (S)-Spinacine (Standard)

    Reference Standards GABA Receptor Neurological Disease
    Spinacine (Standard) is the analytical standard of Spinacine (HY-W067716). This product is intended for research and analytical applications. Spinacine ((S)-Spinacine) is a GABA uptake inhibitor. Spinacine enhances synaptic GABA effects via inhibition of gamma-aminobutyric acid uptake in cerebral cortex slices. Spinacine inhibits reflex responses of ventral roots in isolated spinal cord. Spinacine inhibits motor activity and reduces approaches to water dispensers in conflict situations. Spinacine raises pain sensitivity threshold via subarachnoidal injection .
    Spinacine (Standard)
  • HY-171807

    nAChR STAT Neurological Disease Inflammation/Immunology
    TC-2559 free base is a α4β2 nicotinic acetylcholine receptor (nAChR) agonists with an EC50 of 0.18 μM. TC-2559 free base shows much weaker potencies on the group of b4-containing nAChR subtypes, α2β4, α4β4 and α3β4 receptors, with EC50s in the range of 10-30 µM. TC-2559 free base can increase the discharge of dopamine cells in the ventral tegmental area (VTA) of rats in vitro, enhancing the excitability and aggressive behavior of VTA dopamine neurons. TC-2559 free base inhibits STAT3 to exert anti-inflammatory properties and relieves mice mechanical allodynia and improve rats cognitive deficits. TC-2559 free base can be used for the study of nerve pain .
    TC-2559 free base
  • HY-N13195

    5 alpha Reductase Others
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one shows a 5a-reductase inhibitory activity with an IC50 value of 41.9 μM. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one inhibits the growth of the ventral prostate induced by testosterone in rat. (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one is promising for research of benign prostatic hyperplasia (BPH) as well as other 5α-dihydrotestosterone (DHT)-related disorders, such as acne and male pattern baldness .
    (15α)-15,26-Dihydroxylanosta-7,9(11),24-trien-3-one
  • HY-15691A

    Opioid Receptor mTOR Neurological Disease Metabolic Disease
    PF-4455242 hydrochloride is an orally bioavailable, blood-brain barrier-permeable κ-opioid receptor (KOR) inhibitor. PF-4455242 hydrochloride blocks in vivo effects induced by KOR and MOR agonists, and elicits KOR-independent outward currents in ventral tegmental area neurons. PF-4455242 hydrochloride promotes energy expenditure and activates the hypothalamic mTOR pathway. PF-4455242 hydrochloride attenuates stress-induced behavioral effects and produces antidepressant-like effects. PF-4455242 hydrochloride can be used in studies related to pain, depression, addictive disorders, and obesity induced by estrogen withdrawal .
    PF-4455242 hydrochloride
  • HY-17375R

    Progesterone Receptor Reference Standards Androgen Receptor Endocrinology
    Allylestrenol (Standard) is the analytical standard of Allylestrenol. This product is intended for research and analytical applications. Allylestrenol is an orally active synthetic anti-androgen sexualsteroid. Allylestrenol can prevent miscarriage in vivo. Allylestrenol significantly affects testosterone progesterone level in rat model. Allylestrenol can reduce ventral prostate weight in rat model .
    Allylestrenol (Standard)
  • HY-103197R

    RX821002 hydrochloride (Standard)

    Reference Standards Adrenergic Receptor Neurological Disease
    2-Methoxyidazoxan (monohydrochloride) (Standard) is the analytical standard of 2-Methoxyidazoxan (monohydrochloride). This product is intended for research and analytical applications. 2-Methoxyidazoxan monohydrochloride (RX821002 hydrochloride) is a highly selective alpha 2-adrenoceptor antagonist with little or no imidazoline antagonist effect. RX 821002 has markedly higher affinity for (guinea-pig) alpha 2D-adrenoceptors (pKd 9.7) than for (rabbit) alpha 2A-adrenoceptors (pKd 8.2) .
    2-Methoxyidazoxan monohydrochloride (Standard)
  • HY-W013353

    Endogenous Metabolite Opioid Receptor Neurological Disease
    (RS)-Salsolinol hydrobromide is the hydrobromide form of (±)-Salsolinol (HY-113316). (RS)-Salsolinol hydrobromide is a Dopamine (HY-B0451)-derived endogenous metabolite. (RS)-Salsolinol hydrobromide activates μ-opioid receptors (MORs), reduces GABAergic transmission, increases the excitability of dopamine (DA) neurons, and thus accelerates the sustained firing of neurons in the posterior ventral tegmental area (pVTA) .
    (RS)-Salsolinol hydrobromide
  • HY-W778608R

    Quercetin 7-O-β-glucuronide (Standard)

    Drug Metabolite Reference Standards Inflammation/Immunology
    Dopamine (hydrochloride) (Standard) is the analytical standard of Dopamine (hydrochloride). This product is intended for research and analytical applications. Dopamine hydrochloride (ASL279) is a catecholamine neurotransmitter that is produced in the substantia nigra, ventral tegmental area, and hypothalamus of the brain. Dopamine hydrochloride (ASL279) plays several important roles in the brain and body . Dopamine hydrochloride (ASL279) acts through D2 dopamine receptors to induce endocytosis of VEGFR2, which is critical for promoting angiogenesis .
    Quercetin 7-glucuronide (Standard)
  • HY-13409B

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 monohydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 monohydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 monohydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084 monohydrochloride
  • HY-13409AR

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 (dihydrochloride) (Standard) is the analytical standard of SB 242084 (dihydrochloride). This product is intended for research and analytical applications. SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084 dihydrochloride (Standard)
  • HY-13409R

    5-HT Receptor Neurological Disease Metabolic Disease
    SB 242084 (Standard) is the analytical standard of SB 242084. This product is intended for research and analytical applications. SB 242084 is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage .
    SB 242084 (Standard)
  • HY-100539

    Dopamine Receptor Others
    PD 128907 is a D3 receptor ligand with activities of activating dopamine receptors, inhibiting cell firing, and inhibiting dopamine release. The active (+) enantiomer of PD 128907 has high affinity and selectivity for rat D3 dopamine receptors. PD 128907 inhibits cell firing in the ventral tegmental area and substantia nigra pars compacta with EC50 values of 33nM and 38nM, respectively. PD 128907 also inhibits dopamine release in the caudate putamen with an EC50 of 66nM. However, the selective D2 receptor antagonist L-741,626 has high affinity for receptors activated by PD 128907, indicating that the effects of PD 128907 are more likely on D2 autoreceptors rather than D3 dopamine receptor subtypes.
    PD 128907
  • HY-116219

    Androgen Receptor Endocrinology Cancer
    WB2838 is a non-steroidal androgen-receptor antagonist (IC50: 0.8 μM for partially purified rat prostate cytosol receptor). WB2838 exhibits anti-cancer activity against androgen-responsive breast cancer. WB2838 also shows the inhibitory activity against the growth of the ventral prostate induced by Testosterone propionate .
    WB2838
  • HY-D3420

    Fluorescent Dye Neurological Disease
    Neuro-DiI is a red retrograde Fluorescent tracer. Neuro-DiI is transported retrogradely to the cell bodies in the ventral tegmental area and labels ventral tegmental area neurons with red fluorescence .
    Neuro-DiI
  • HY-180409

    Androgen Receptor Cancer
    YM580 is a potent, orally active and selective Androgen Receptor (AR) antagonist (IC50 = 0.11 μM, hAR Ki = 4.6 nM, rAR Ki = 6.2 nM). YM580 exhibits good selectivity over PR, GR, and ERα (Kis > 3300 nM). YM580 decreases ventral prostate weight in mature intact rats dose-dependently without affecting serum testosterone levels. YM580 can be used for the research of prostate cancer .
    YM580
  • HY-119436

    Androgen Receptor Metabolic Disease
    LG-120907 is a selective androgen receptor (AR) antagonist with a Ki value of 26 nM. LG-120907 inhibits Testosterone-induced increases in ventral prostate (VP) tissue weight and seminal vesicles (SV) tissue weight in vivo .
    LG-120907
  • HY-180410

    Androgen Receptor Endocrinology
    YM-1758735 is an orally active androgen receptor (AR) antagonist with an IC50 of 0.2 μM. YM-1758735 inhibits AR-mediated transcriptional activation. YM-1758735 can be used for the research of prostate .
    YM-1758735
  • HY-129245

    Hoe 175

    Endogenous Metabolite Neurological Disease
    Razobazam (Hoe 175) is a benzodiazepine derivative with cognitive activity. Razobazam has been shown to improve learning performance in socially deprived rats. Razobazam increased avoidance scores by 18% after training. Razobazam caused significant changes in the optical density of certain areas of the rat brain, including a 22% decrease in the lateral habenula and a 25% increase in the ventral tegmental area. Razobazam also caused a 13% increase in optical density in the prefrontal cortex of rats .
    Razobazam
  • HY-123446

    Phosphodiesterase (PDE) Neurological Disease
    JNJ-42259152 is a phosphodiesterase 10A (PDE10A) positron emission tomography (PET) tracer that is specific for PDE10A activity. JNJ-42259152 can be dynamically scanned in healthy volunteers to assess its kinetic properties in the brain. The half-life of JNJ-42259152 in the blood is an average of 90 minutes. JNJ-42259152 has demonstrated reliable binding potential (BPND) in different target areas (such as the lentiform nucleus, caudate nucleus, ventral striatum, etc.), providing an important tool for studying neuropsychiatric diseases .
    JNJ-42259152
  • HY-179646

    Toll-like Receptor (TLR) NO Synthase NF-κB TNF Receptor Interleukin Related Neurological Disease
    CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease .
    CIAC101
  • HY-182401

    ERK Akt Neurological Disease
    NS-417 free base is an ERK1, ERK2, and Akt kinase activator with neuroprotective, neurite outgrowth potentiating, and dopaminergic cell population enhancing activity. NS-417 free base enhances activation of ERK1, ERK2, and Akt kinase via growth factor stimulation. NS-417 free base rescues cells from growth factor withdrawal-induced death, stimulates neurite outgrowth, increases tyrosine hydroxylase-positive cell counts, and displays neurotrophic-like activity in in vitro models. NS-417 free base can be used for the research of parkinson’s disease .
    NS-417 free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: